Punto Health is a technology company.
Punto Health has raised $700K across 1 funding round.
Punto Health has raised $700K in total across 1 funding round.
Punto Health is a London-based healthtech startup founded in 2023 that builds an AI-driven, full-stack platform for early detection and personalized support in dementia and cognitive care[1][2][4]. The platform includes PuntoCare for patients with cognitive impairments (from mild to advanced dementia) and their caregivers, offering personalized care plans with cognitive exercises, activity recommendations, nutrition tips, and speech-based digital biomarkers for tracking cognitive status[2][3]. PuntoClinic provides clinician dashboards for remote monitoring, symptom tracking, and coordination between patients, carers, and healthcare professionals[3][9]. It serves patients, families, and providers in the UK and Spain, addressing gaps in post-diagnostic support like insufficient information, emotional guidance, and proactive care amid rising dementia costs (projected at £90 billion in the UK by 2040)[1][3]. Recent momentum includes a $2.7M (£2M/€2.3M) seed round in December 2025 co-led by Shilling VC and Plus Partners, plus a €100K NN Group award in June 2025, fueling product development, UK/Spain expansion, and clinical validations starting March 2025[1][7][8].
Punto Health emerged from personal experience when co-founder and CEO Anna Muñoz-Farré witnessed dementia's impact on her grandfather, revealing systemic gaps in healthcare like reactive care and lack of family support[7]. Engineers Muñoz-Farré and Jack Eckersley (motivated by neurodegenerative diseases' toll on families and systems) founded the company in London in 2023, leveraging their expertise in scalable AI systems—Muñoz-Farré from Google accel and Eckersley in robust tech builds[2][4][5]. Early traction came via co-design with patients and carers, strong NHS partnerships (e.g., Enfield and Greenwich Memory Services), and collaborations in Spain (Ace Alzheimer Center Barcelona, Hospital del Mar, Hospital General de Granollers)[1][3]. Pivotal moments include winning the €100K NN Social Innovation Award in June 2025 for proactive dementia support and securing the seed round for commercial rollout, with user Maria Rosa completing over 1,000 exercises in 8 weeks[3][7].
Punto Health rides the AI healthtech wave in neurodegenerative care, targeting dementia's explosion (78M diagnoses by 2030, 1-in-2 lifetime risk) amid aging populations and NHS digital priorities for remote, proactive support[3][7]. Timing aligns with post-diagnostic gaps—e.g., UK's £90B cost by 2040—and AI's rise for biomarkers/remote monitoring, enabling independent living and cost savings[3]. Market forces like insurer/pharma demand for scalable solutions and Europe's fragmented care systems favor its bilingual, clinician-validated approach[1][2]. It influences the ecosystem by pioneering "full-stack" dementia platforms, fostering NHS/EU collaborations, and proving AI's shift from reactive to preventive care, potentially reducing long-term burdens[1][3][8].
Punto Health is poised for rapid scale post-seed, with UK/Spain pilots proving ROI via quality-of-life boosts and cost reductions, targeting B2B then consumer expansion[2][3]. Trends like AI diagnostics, remote care mandates, and €100B+ global dementia markets will propel growth, especially with mentorship from investors like NN Group/Rubio[1][7]. Influence may evolve into a European standard-setter, integrating pharma trials and broader cognitive apps, transforming family crises into empowered management[7]. This seed momentum builds on personal origins to redefine dementia as manageable through AI.
Punto Health has raised $700K in total across 1 funding round.
Punto Health's investors include Ada Ventures.
Punto Health has raised $700K across 1 funding round. Most recently, it raised $700K Seed in May 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2024 | $700K Seed | Ada Ventures |